---
title: July News Round Up
description: Catch up on the latest eye care news! From innovations to tips, stay informed on everything you need for healthier eyes.
---

[Vision Executives Blog](https://visionexecutives.com/blog)

# [July News Round Up](https://visionexecutives.com/blog/july-news-round-up)

 Written by [Vision Executives](https://visionexecutives.com/blog/author/vision-executives) | Aug 9, 2024 8:14:19 AM

𝐉𝐮𝐥𝐲 𝐍𝐞𝐰𝐬 𝐑𝐨𝐮𝐧𝐝 𝐔𝐩

👀 𝐁𝐚𝐮𝐬𝐜𝐡 & 𝐋𝐨𝐦𝐛 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐓𝐫𝐮𝐤𝐞𝐫𝐚 𝐌𝐞𝐝𝐢𝐜𝐚𝐥: 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐃𝐫𝐲 𝐄𝐲𝐞 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬  
[Bausch + Lomb](https://www.linkedin.com/company/bausch-%26-lomb/) has acquired [Trukera Medical](https://www.linkedin.com/company/trukera-medical/), an ophthalmic diagnostics leader, through an affiliate. This acquisition introduces the innovative ScoutPro, a portable osmolarity system launched in October 2022. The ScoutPro, Trukera’s first product since rebranding, provides an all-in-one solution for measuring tear osmolarity to diagnose dry eye disease (DED).

As the only portable osmometer in the U.S., ScoutPro enhances diagnostics with its automated capabilities. Bausch & Lomb expects this "tuck-in" acquisition to strengthen their surgical offerings and solidify their leading position in the dry eye treatment market. Integrating ScoutPro’s technology marks a significant step in advancing eye care.

👀 𝐄𝐬𝐬𝐢𝐥𝐨𝐫𝐋𝐮𝐱𝐨𝐭𝐭𝐢𝐜𝐚 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐌𝐚𝐣𝐨𝐫𝐢𝐭𝐲 𝐒𝐭𝐚𝐤𝐞 𝐢𝐧 𝐇𝐞𝐢𝐝𝐞𝐥𝐛𝐞𝐫𝐠 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠   
[EssilorLuxottica](https://www.linkedin.com/company/essilorluxottica/) has acquired an 80% stake in [Heidelberg Engineering](https://www.linkedin.com/company/heidelberg-engineering/), a leader in optical coherence tomography (OCT) and digital surgical navigation technologies. Heidelberg Engineering will continue operating independently under its brand, enhancing EssilorLuxottica's capabilities in early detection and diagnosis.

👀 𝐀𝐍𝐈 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐭𝐨 𝐀𝐜𝐪𝐮𝐢𝐫𝐞 𝐀𝐥𝐢𝐦𝐞𝐫𝐚 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐟𝐨𝐫 $381 𝐌𝐢𝐥𝐥𝐢𝐨𝐧   
[ANI Pharmaceuticals, Inc.](https://www.linkedin.com/company/ani-pharmaceuticals-inc-/) will acquire [Alimera Sciences Ophthalmologie GmbH](https://www.linkedin.com/company/alimera-sciences-ophthalmologie-gmbh/) for $381 million, aiming to enhance its Rare Disease business and strengthen its presence in ophthalmology, specifically in DME and Uveitis. The deal is expected to finalise by late Q3 2024, pending regulatory approvals, with projected revenues of $105 million in 2024.

👀 𝐓𝐡𝐞 𝐄𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐔𝐊 𝐄𝐲𝐞 𝐂𝐚𝐫𝐞: 𝐁𝐚𝐥𝐚𝐧𝐜𝐢𝐧𝐠 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐚𝐧𝐝 𝐍𝐇𝐒 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬  
Nearly 60% of NHS cataract surgeries are now performed by private providers to address the COVID-19 backlog, reducing waiting times but causing controversy. A survey revealed 58% of hospital eye units believe this shift negatively impacts patient care. The role of High Street optometrists in providing primary eye care has been emphasized, suggesting they could support community and tertiary care.

👀 𝐀𝐎𝐏 𝐎𝐮𝐭𝐥𝐢𝐧𝐞𝐬 𝐊𝐞𝐲 𝐏𝐫𝐢𝐨𝐫𝐢𝐭𝐢𝐞𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐍𝐞𝐱𝐭 𝐆𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭   
Ahead of the UK general election, the Association of Optometrists (AOP) has highlighted three priorities:  
👁 Expanding community eye care services.  
👁 Updating the medication prescribing powers of optometrists.  
👁 Investing in IT infrastructure to improve image sharing and communication between clinicians

[View full post](https://visionexecutives.com/blog/july-news-round-up)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Vision Executives"
  },
  "dateModified" : "2024-08-09T08:14:19.705Z",
  "datePublished" : "2024-08-09T08:14:19Z",
  "headline" : "July News Round Up",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1080,
    "url" : "https://139544819.fs1.hubspotusercontent-eu1.net/hubfs/139544819/July%20News%20Round%20Up.png",
    "width" : 1080
  },
  "mainEntityOfPage" : "https://visionexecutives.com/blog/july-news-round-up",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Vision Executives Blog"
  }
}
```